"MindMed doses first subject in trial of tablets for generalised anxiety disorder" was originally created and published by ...

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...

Mind Medicine Inc., a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health ...

MindMed Inc. has announced the dosing of the first patient in its phase 3 Voyage study of MM120 ODT, a pharmaceutically ...

Charles Schwab Investment Management Inc. grew its holdings in shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free ...

Mind Medicine (MNMD) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...

(New York Times) A small randomized trial in China showed that transcutaneous auricular vagus nerve stimulation improved ...

Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...

Javier Muniz, M.D. - Vice President of Research and Development Strategy, MindMed (Photo: Business Wire) ...

Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...